Net Loss of Oxygenta Pharmaceutical reported to Rs 1.36 crore in the quarter ended June 2024 as against net loss of Rs 4.56 crore during the previous quarter ended June 2023. Sales rose 83.97% to Rs 12.62 crore in the quarter ended June 2024 as against Rs 6.86 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales12.626.86 84 OPM %-14.03-53.06 - PBDT-2.16-3.93 45 PBT-2.81-4.43 37 NP-1.36-4.56 70 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live News

Net profit of Oxygenta Pharmaceutical reported to Rs 8.02 crore in the quarter ended March 2024 as against net loss of Rs 4.29 crore during the previous quarter ended March 2023. Sales rose 28.82% to Rs 10.55 crore in the quarter ended March 2024 as against Rs 8.19 crore during the previous quarter ended March 2023.For the full year,net loss reported to Rs 3.48 crore in the year ended March 2024 as against net loss of Rs 11.57 crore during the previous year ended March 2023. Sales rose 27.91% to Rs 39.64 crore in the year ended March 2024 as against Rs 30.99 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales10.558.19 29 39.6430.99 28 OPM %-15.26-27.47 --24.47-22.98 - PBDT-2.19-3.19 31 -11.25-8.59 -31 PBT-2.83-4.04 30 -13.91-10.64 -31 NP8.02-4.29 LP -3.48-11.57 70 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 30 May 2024Powered by Capital Market - Live News

Oxygenta Pharmaceutical announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 May 2024 .Powered by Capital Market - Live News